Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S. Food & Drug Administration (FDA) Priority Review and European Medicines Agency (EMA) review Late-stage pipeline continues to advance FY2026 full-year outlook upgraded to reflect foreign exchange (FX) […]
Read original article on Financial Post →Related news
- Increase in the price of the simplified tender offer for North Atlantic Energies shares
- Shell plc Third Quarter 2026 Interim Dividend
- Shell announces commencement of a share buyback programme
- SHELL PLC 2027 INTERIM DIVIDEND TIMETABLE
- SHELL PLC 3rd QUARTER 2026 AND NINE MONTHS UNAUDITED RESULTS
- Shell plc publishes third quarter 2026 press release
- IQM Demonstrates Entanglement Across a Complete 54-Qubit Processor, Bringing Full-Chip Performance to Cloud Users
-
AB InBev Reports Third Quarter 2026 Results
Business
Corporate
Belgium